Obulytix

[flanders.bio @flandersbio]

Welcome to our new member Obulytix!
Obulytix is a #biotechnology company focused on the discovery and development of a groundbreaking class of enzyme-based #antibiotics to combat the most severe antibiotic-resistant bacteria.
#antibioticresistance
https://t.co/XODhqqva9Z

[Obulytix @obulytix]

We are excited to join and to speak at this exciting forum for the AMR community #AMRconference

[Obulytix @obulytix]

#Phage #lysins killing bacteria :-)

[Phage Directory @phagedirectory]

.@BriersYves will head up @obulytix, a company based on the #phage lysin-based platform leveraging AI to tackle bacterial infections he co-developed at @ugent & @KU_Leuven. Obulytix has attracted $4 M investment from @Boehringer, Qbic, & Gemma Frisius Fund
https://t.co/Noz31k9Tt3

[Obulytix @obulytix]

We are grateful to the @Boehringer Ingelheim Venture Fund for investing in our biotech start-up, their trust in the team and our technology for custom-made development of engineered #phage #lysins. #AMR #precisionantibiotics

[Boehringer Ingelheim @Boehringer]

#News: Our Venture Fund invests in @Obulytix to develop antimicrobial resistant (#AMR) infection treatments. We are committed to invest EUR 200 million to combat emerging infectious diseases.
Learn more: https://t.co/D92dnGGRlK

#BacterialInfections #Innovation

[Obulytix @obulytix]

Thank you for putting the spots on the global threat coming from #antibiotic resistance #AMR and the innovative solutions we are working on. #phagelysin

[Obulytix @obulytix]

Great to see the significant investment by Boehringer Ingelheim Venture Fund, Qbic Fund | Venture Capital and GEMMA FRISIUS - FONDS K.U.LEUVEN in Obulytix featured by De Tijd. https://t.co/tfNBuC2VUO